The estimated Net Worth of Iain D. Dukes is at least $1.47 Million dollars as of 20 February 2024. Iain Dukes owns over 32,000 units of Iovance Biotherapeutics Inc stock worth over $504,900 and over the last 7 years he sold IOVA stock worth over $0. In addition, he makes $960,725 as Chairman of the Board at Iovance Biotherapeutics Inc.
Sign up
Iain Dukes IOVA stock SEC Form 4 insiders trading
Iain has made over 3 trades of the Iovance Biotherapeutics Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he bought 32,000 units of IOVA stock worth $292,800 on 20 February 2024.
The largest trade he's ever made was buying 32,000 units of Iovance Biotherapeutics Inc stock on 20 February 2024 worth over $292,800. On average, Iain trades about 4,500 units every 158 days since 2017. As of 20 February 2024 he still owns at least 54,000 units of Iovance Biotherapeutics Inc stock.
You can see the complete history of Iain Dukes stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Iain Dukes biography
Dr. Iain Dukes Dukes D.Phil. serves as Chairman of the Board of the Company. Dr. Dukes joined our Board of Directors on August 4, 2016 and was appointed Chairman of the Board on August 16, 2016. Dr. Dukes currently is a Venture Partner at OrbiMed Advisors LLC. He previously served as Senior Vice President and Head of Business Development and Licensing for Merck Research Laboratories through May 2016. He joined Merck in August 2013. Prior to joining Merck, Dr. Dukes was Vice President of External Research & Development at Amgen, from August 2010 to August 2013. From 2007 to 2010, Dr. Dukes was the President and Chief Executive Officer, and a member of the board of directors, of Essentialis Therapeutics, a clinical stage biotechnology company focused on the development of breakthrough medicines for the treatment of rare metabolic diseases. From 2000 to 2007, Dr. Dukes was Vice President of Scientific and Technology Licensing at GlaxoSmithKline, and prior to that, from 1990 to 1999, he held various positions at Glaxo Wellcome, including Head of Exploratory Development for Metabolic and Urogenital Diseases and Head of Ion Channel Drug Discovery Group. Dr. Dukes holds Master of Jurisprudence and Doctorate of Philosophy degrees from the University of Oxford, a Master of Science degree in Cardiovascular Studies from the University of Leeds and a Bachelor of Science degree in Pharmacology from the University of Bath.
What is the salary of Iain Dukes?
As the Chairman of the Board of Iovance Biotherapeutics Inc, the total compensation of Iain Dukes at Iovance Biotherapeutics Inc is $960,725. There are 3 executives at Iovance Biotherapeutics Inc getting paid more, with Maria Fardis having the highest compensation of $4,107,960.
How old is Iain Dukes?
Iain Dukes is 61, he's been the Chairman of the Board of Iovance Biotherapeutics Inc since 2016. There are 2 older and 12 younger executives at Iovance Biotherapeutics Inc. The oldest executive at Iovance Biotherapeutics Inc is Merrill McPeak, 84, who is the Independent Director.
What's Iain Dukes's mailing address?
Iain's mailing address filed with the SEC is C/O IOVANCE BIOTHERAPEUTICS, INC., 825 INDUSTRIAL ROAD, SUITE 400, SAN CARLOS, CA, 94070.
Insiders trading at Iovance Biotherapeutics Inc
Over the last 8 years, insiders at Iovance Biotherapeutics Inc have traded over $0 worth of Iovance Biotherapeutics Inc stock and bought 22,614,553 units worth $159,655,586 . The most active insiders traders include Wayne P. Rothbaum, Merrill A Mcpeak, and Timothy E Morris. On average, Iovance Biotherapeutics Inc executives and independent directors trade stock every 37 days with the average trade being worth of $3,815,146. The most recent stock trade was executed by Frederick G Vogt on 3 September 2024, trading 57,292 units of IOVA stock currently worth $535,680.
What does Iovance Biotherapeutics Inc do?
iovance biotherapeutics is focused on the development and commercialization of novel cancer immunotherapies based on tumor infiltrating lymphocytes (til). this approach, also known as adoptive t-cell therapy, was initially developed by dr. steven a. rosenberg at the national cancer institute (nci). in phase 2 clinical trials conducted at the nci, 56% and 24% of patients treated with this technology were reported by nci to have achieved objective and complete response criteria, respectively. our lead product candidate is an autologous, ready-to-infuse cell therapy, that has demonstrated distinctive efficacy in the treatment of metastatic melanoma. in addition to metastatic melanoma, carcinoma of the head and neck and cervical cancer our til therapy technology is potentially applicable to many other tumor types, including ovarian, breast, bladder, colorectal and other cancers. as we continue advancing our current clinical programs through the introduction of manufacturing and logistical
What does Iovance Biotherapeutics Inc's logo look like?
Complete history of Iain Dukes stock trades at Iovance Biotherapeutics Inc
Iovance Biotherapeutics Inc executives and stock owners
Iovance Biotherapeutics Inc executives and other stock owners filed with the SEC include:
-
Maria Fardis,
President, Chief Executive Officer and Director -
Friedrich Graf Finckenstein,
Chief Medical Officer -
Frederick Vogt,
General Counsel, Corporate Secretary -
Iain Dukes,
Chairman of the Board -
Michael Weiser,
Independent Director -
Jean-Marc Bellemin M.B.A.,
Chief Financial Officer & Principal Accounting Officer -
Dr. Friedrich Graf Finckenstein M.D.,
Chief Medical Officer -
Dr. Frederick G. Vogt Esq., J.D., Ph.D.,
Interim Pres, CEO, Gen. Counsel & Corp. Sec. -
Merrill McPeak,
Independent Director -
Ryan Maynard,
Independent Director -
Athena Countouriotis,
Director -
Michael Swartzburg,
Interim Principal Financial Officer and Principal Accounting Officer -
Sara Pellegrino,
IR Contact Officer -
Wayne Rothbaum,
Independent Director -
Dr. Elma S. Hawkins,
Advisor to the Board -
Madan Jagasia,
Sr. VP of Medical Affairs -
James Ziegler,
Sr. VP of Commercial -
Howard B. Johnson,
Sr. VP of Corp. Devel., Alliance Management & Program Management -
Dr. Igor P. Bilinsky,
Chief Operating Officer -
Timothy E Morris,
Chief Financial Officer -
Jean Marc Bellemin,
Chief Financial Officer -
Igor Bilinsky,
Chief Operating Officer -
Wendy L Yarno,
Director -
Wendy L Dixon,
Director